Histidine decarboxylase promotes acquired cisplatin resistance in gastric cancer cells
World Journal of Gastroenterology · 16.11.2026
DOI: 10.3748/wjg.124512 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 16.11.2026. Verfasst von Lian-Lian Hong und 3 weiteren Autor:innen.
Abstract (Originalsprache)
BACKGROUNDCisplatin-based chemotherapy is widely used in gastric cancer (GC), but acquired resistance substantially compromises treatment outcomes.Metabolic reprogramming plays an important role in cisplatin resistance in GC.Although histidine metabolism dysregulation has been reported in various cancers, the function of histidine decarboxylase (HDC) in modulating this process remains unclear. AIMTo characterize the key histidine-metabolizing enzyme involved in cisplatin resistance, discover the resistance mechanisms, and identify potential therapeutic targets in GC. METHODSCisplatin-resistant AGS/DDP and HGC-27/DDP cells were constructed, and tandem mass tag-based quantitative proteomic techniques combined with liquid chromatographytandem mass spectrometry were applied to screen and evaluate differentially expressed metabolism-related genes (fold-change > 1.2, P < 0.05).Cellular functional assays, including small interfering RNA knockdown, Western blotting, Cell Counting Kit-8 drug-sensitivity assays, and flow cytometric apoptosis assays, as well as tissue microarray analysis and immunohistochemistry, were performed to evaluate the association between differentially expressed proteins (DEPs) and cisplatin resistance in GC. RESULTSDEPs in cisplatin-resistant cells were enriched in histidine metabolism, oxidative phosphorylation, and fatty acid metabolism.Knockdown or pharmacological inhibition 4 / 34 of HDC reversed cisplatin resistance in resistant cells.The gene was abnormally upregulated in GC tissues and implied a poor prognosis. CONCLUSIONThis study highlights the role of histidine metabolism in cisplatin resistance in GC.Targeting HDC may be a promising therapeutic strategy for cisplatin-resistant GC, while also providing insight into the mechanism of resistance and potential therapeutic targets.
Zitieren
APA
Hong, L., Han, J., Wang, Y., & Lv, H. (2026). Histidine decarboxylase promotes acquired cisplatin resistance in gastric cancer cells. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.124512
Vancouver
Hong L, Han J, Wang Y, Lv H. Histidine decarboxylase promotes acquired cisplatin resistance in gastric cancer cells. World Journal of Gastroenterology. 2026. doi:10.3748/wjg.124512
BibTeX
@article{Hong2026,
author = {Hong, Lian-Lian and Han, Jing and Wang, Yi-Ping and Lv, Hang},
title = {Histidine decarboxylase promotes acquired cisplatin resistance in gastric cancer cells},
journal = {World Journal of Gastroenterology},
year = {2026},
doi = {10.3748/wjg.124512}
}
EUVIMED